Correction to: Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2 (Cancer Science, (2013), 104, 6, (750-759), 10.1111/cas.12132);Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2

Cancer Science

Volumn 104, Issue 6, 2013, Pages 750-759

  Wang, Shanshan ^a   Zhu, Yu ^b   He, Hongyong ^b   Liu, Jing ^c   Xu, Le ^b   Zhang, Heng ^b   Liu, Haiou ^a   Liu, Weisi ^a   Liu, Yidong ^a   Pan, Deng ^a   Chen, Lin ^a   Wu, Qian ^a   Xu, Jiejie ^a   Gu, Jianxin ^a  

^a Institute of Pathogenic Biology   (China)

^b FUDAN UNIVERSITY   (China)

^c NANTONG MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; HISTONE METHYLTRANSFERASE; PROTEASOME; SHORT HAIRPIN RNA; SORAFENIB; TRANSCRIPTION FACTOR EZH2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; EPIGENETICS; GENE DELETION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METHYLATION;

EID: 84878209456     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.15203     Document Type: Erratum

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
3. Llovet JM, Burroughs A, J B. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
4. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-108.
5. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8: 292-301.
7. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-28.
8. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59: 111-37.
9. Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43.
10. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-64.
11. Suva ML, Riggi N, Janiszewska M et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-8.
12. Sudo T, Utsunomiya T, Mimori K et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92: 1754-8.
13. Weikert S, Christoph F, Kollermann J et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005; 16: 349-53.
14. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-73.
15. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11.
16. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-35.
17. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
18. Sasaki M, Ikeda H, Itatsu K et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008; 88: 873-82.
19. Chen Y, Lin MC, Wang H et al. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics 2007; 7: 3097-104.
20. Zheng F, Liao YJ, Cai MY et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278-89.
21. Cheng AS, Lau SS, Chen Y et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res 2011; 71: 4028-39.
22. Au SL, Wong CC, Lee JM et al. Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs to promote liver cancer metastasis. Hepatology 2012; 56: 622-31.
23. Chen Y, Lin MC, Yao H et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007; 46: 200-8.
24. Yang F, Zhang L, Huo XS et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011; 54: 1679-89.
25. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011; 30: 2670-8.
26. Chiba T, Suzuki E, Negishi M et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012; 130: 2557-67.
27. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-63.
28. Liu H, Xu J, Zhou L et al. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res 2011; 71: 7547-57.
29. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004; 23: 5759-69.
30. Xu J, Yun X, Jiang J et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology 2010; 52: 142-54.
31. Xu J, Liu H, Chen L et al. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology 2012; 143: 199-212.
32. Zhang W, Xu W, Xiong S. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 2011; 187: 1764-77.
33. Zhang W, Xu W, Xiong S. Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol 2010; 184: 6465-78.
34. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.
35. Fujii S, Tokita K, Wada N et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011; 30: 4118-28.
36. Chen H, Gu X, Liu Y et al. PDGF signalling controls age-dependent proliferation in pancreatic beta-cells. Nature 2011; 478: 349-55.
37. Lu C, Han HD, Mangala LS et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2011; 18: 185-97.
38. Wu SC, Zhang Y. Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J Biol Chem 2011; 286: 28511-9.
39. Meng XW, Lee SH, Dai H et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007; 282: 29831-46.
40. Chen YL, Lv J, Ye XL et al. Sorafenib inhibits transforming growth factor beta1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2011; 53: 1708-18.
41. Chen KF, Tai WT, Liu TH et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010; 16: 5189-99.
42. Coriat R, Nicco C, Chereau C et al. Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production in vitro and in vivo. Mol Cancer Ther 2012; 11: 2284-93.
43. Yu J, Cao Q, Mehra R et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-31.
44. Min J, Zaslavsky A, Fedele G et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-94.
45. Herranz N, Pasini D, Diaz VM et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008; 28: 4772-81.
46. Kotake Y, Cao R, Viatour P et al. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007; 21: 49-54.